SCYNEXIS announces first patient dosed in phase 3 open-label study
SCYNEXIS announced dosing of the first patient with a Candida auris infection, an emerging life-threatening and multidrug-resistant fungal pathogen, in a Phase 3 open-label study evaluating oral ibrexafungerp (formerly SCY-078) in patients with candidiasis caused by C. auris. October 15, 2018